甲状腺癌分子诊断的最新进展
Recent advances in molecular diagnosis of thyroid cancer.
作者信息
Legakis Ioannis, Syrigos Konstantinos
机构信息
Department of Endocrinology and Metabolism, Henry Dunant Hospital, Thision, 11851 Athens, Greece.
出版信息
J Thyroid Res. 2011;2011:384213. doi: 10.4061/2011/384213. Epub 2011 Mar 23.
Abstract
Recent molecular studies have described a number of abnormalities associated with the progression and dedifferentiation of thyroid carcinoma. These distinct molecular events are often associated with specific stages of tumor development. In particular, remarkable advances have occurred in several major biological areas of thyroid cancer, including the molecular alterations for the loss of radioiodine avidity of thyroid cancer, the pathogenic role of the MAP kinase and PI3K/Akt pathways and their related genetic alterations, and the aberrant methylation of functionally important genes in thyroid tumorigenesis and pathogenesis. Recognition of these features is crucial to the management of patients with thyroid cancer. Novel treatments are being designed based on our enhanced understanding of this disease process.
摘要
最近的分子研究描述了一些与甲状腺癌进展和去分化相关的异常情况。这些独特的分子事件通常与肿瘤发展的特定阶段相关。特别是，甲状腺癌的几个主要生物学领域取得了显著进展，包括甲状腺癌放射性碘摄取丧失的分子改变、MAP激酶和PI3K/Akt信号通路的致病作用及其相关基因改变，以及甲状腺肿瘤发生和发病机制中功能重要基因的异常甲基化。认识到这些特征对于甲状腺癌患者的管理至关重要。基于我们对这一疾病过程的深入理解，正在设计新的治疗方法。
相似文献
1
Recent advances in molecular diagnosis of thyroid cancer.甲状腺癌分子诊断的最新进展
J Thyroid Res. 2011;2011:384213. doi: 10.4061/2011/384213. Epub 2011 Mar 23.
2
Recent advances in molecular biology of thyroid cancer and their clinical implications.甲状腺癌分子生物学的最新进展及其临床意义。
Otolaryngol Clin North Am. 2008 Dec;41(6):1135-46, ix. doi: 10.1016/j.otc.2008.07.001.
3
Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer.甲状腺癌中磷脂酰肌醇-3-激酶/蛋白激酶 B 通路的遗传改变。
Thyroid. 2010 Jul;20(7):697-706. doi: 10.1089/thy.2010.1646.
4
Genetic considerations in thyroid cancer.甲状腺癌的遗传学考量
Cancer Control. 2006 Apr;13(2):111-8. doi: 10.1177/107327480601300205.
5
Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors.甲状腺肿瘤中PTEN基因甲基化与磷脂酰肌醇3-激酶/AKT信号通路基因改变的相关性
Cancer. 2008 Nov 1;113(9):2440-7. doi: 10.1002/cncr.23869.
6
Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways.通过靶向主要信号通路诱导甲状腺癌细胞的甲状腺基因表达和放射性碘摄取。
J Clin Endocrinol Metab. 2010 Feb;95(2):820-8. doi: 10.1210/jc.2009-1888. Epub 2009 Dec 11.
7
Gene methylation in thyroid tumorigenesis.甲状腺肿瘤发生中的基因甲基化
Endocrinology. 2007 Mar;148(3):948-53. doi: 10.1210/en.2006-0927. Epub 2006 Aug 31.
8
[Genetic alterations in MAPK and PI3K/Akt signaling pathways and the generation, progression, diagnosis and therapy of thyroid cancer].[丝裂原活化蛋白激酶（MAPK）和磷脂酰肌醇-3激酶/蛋白激酶B（PI3K/Akt）信号通路中的基因改变与甲状腺癌的发生、发展、诊断及治疗]
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2012 Dec;29(6):1221-5.
9
Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.甲状腺癌中磷脂酰肌醇3-激酶/蛋白激酶B信号通路中的基因改变及其相互关系
Clin Cancer Res. 2007 Feb 15;13(4):1161-70. doi: 10.1158/1078-0432.CCR-06-1125.
10
Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications.黑色素瘤细胞中甲状腺基因表达的诱导及放射性碘摄取：新的治疗意义。
PLoS One. 2009 Jul 10;4(7):e6200. doi: 10.1371/journal.pone.0006200.
引用本文的文献
1
Liquid Biopsy as a Minimally Invasive Source of Thyroid Cancer Genetic and Epigenetic Alterations.液体活检作为甲状腺癌遗传和表观遗传改变的微创来源
Int J Mol Cell Med. 2019 Winter;8(Suppl1):19-29. doi: 10.22088/IJMCM.BUMS.8.2.19. Epub 2019 May 29.
2
The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.HRAS 和 CDK4/6 抑制剂在间变性甲状腺癌细胞系中的疗效。
J Endocrinol Invest. 2019 May;42(5):527-540. doi: 10.1007/s40618-018-0947-4. Epub 2018 Sep 6.
3
Suppression of inhibits malignant proliferation of human papillary thyroid carcinoma cell.对……的抑制作用可抑制人甲状腺乳头状癌细胞的恶性增殖。 （你提供的原文似乎不完整，“Suppression of”后面缺少具体内容）
Oncol Lett. 2018 Jun;15(6):9202-9208. doi: 10.3892/ol.2018.8496. Epub 2018 Apr 13.
4
Association of p53 (-16ins-pro) haplotype with the decreased risk of differentiated thyroid carcinoma in Iranian-Azeri patients.p53（-16ins-pro）单倍型与伊朗-阿塞拜疆患者分化型甲状腺癌风险降低的关联。
Pathol Oncol Res. 2015 Apr;21(2):449-54. doi: 10.1007/s12253-014-9846-y. Epub 2014 Nov 20.
5
Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma.PTEN、PI3K、MTOR和KRAS表达的评估及其与分化型甲状腺癌的临床和预后相关性
Contemp Oncol (Pozn). 2014;18(4):234-40. doi: 10.5114/wo.2014.43803. Epub 2014 Jul 4.
6
Candidate agents for papillary thyroid cancer identified by gene expression analysis.基因表达分析鉴定的甲状腺乳头癌候选药物。
Pathol Oncol Res. 2013 Jul;19(3):597-604. doi: 10.1007/s12253-013-9625-1. Epub 2013 Mar 22.
7
Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma.评估犬大汗腺肛门囊腺癌和甲状腺癌中血管内皮生长因子受体 2、血小板衍生生长因子受体-α和-β、KIT 和 RET 的表达和功能。
BMC Vet Res. 2012 May 25;8:67. doi: 10.1186/1746-6148-8-67.
本文引用的文献
1
Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules.分子检测在改善甲状腺结节细针穿刺诊断中对突变的检测作用。
J Clin Endocrinol Metab. 2009 Jun;94(6):2092-8. doi: 10.1210/jc.2009-0247. Epub 2009 Mar 24.
2
Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers.分化型甲状腺癌和髓样甲状腺癌化疗的进展
J Clin Endocrinol Metab. 2009 May;94(5):1493-9. doi: 10.1210/jc.2008-0923. Epub 2009 Mar 3.
3
Phase II trial of sorafenib in metastatic thyroid cancer.索拉非尼用于转移性甲状腺癌的II期试验。
J Clin Oncol. 2009 Apr 1;27(10):1675-84. doi: 10.1200/JCO.2008.18.2717. Epub 2009 Mar 2.
4
Active contours guided by echogenicity and texture for delineation of thyroid nodules in ultrasound images.基于回声性和纹理引导的活动轮廓用于超声图像中甲状腺结节的勾画。
IEEE Trans Inf Technol Biomed. 2009 Jul;13(4):519-27. doi: 10.1109/TITB.2008.2007192. Epub 2008 Oct 31.
5
The value of positron emission tomography (PET) in the management of patients with thyroid cancer.正电子发射断层扫描（PET）在甲状腺癌患者管理中的价值。
Best Pract Res Clin Endocrinol Metab. 2008 Dec;22(6):1047-59. doi: 10.1016/j.beem.2008.10.001.
6
Risk-adapted management of thyroid cancer.甲状腺癌的风险适应性管理。
Endocr Pract. 2008 Sep;14(6):764-74. doi: 10.4158/EP.14.6.764.
7
Induction of sodium iodide symporter gene and molecular characterisation of HNF3 beta/FoxA2, TTF-1 and C/EBP beta in thyroid carcinoma cells.甲状腺癌细胞中碘化钠转运体基因的诱导以及肝细胞核因子3β/FoxA2、甲状腺转录因子-1和CCAAT增强子结合蛋白β的分子特征分析
Br J Cancer. 2008 Sep 2;99(5):781-8. doi: 10.1038/sj.bjc.6604544.
8
Phase II trial of sorafenib in advanced thyroid cancer.索拉非尼用于晚期甲状腺癌的II期试验。
J Clin Oncol. 2008 Oct 10;26(29):4714-9. doi: 10.1200/JCO.2008.16.3279. Epub 2008 Jun 9.
9
BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.BRAFV600E突变而非RET/PTC重排与甲状腺乳头状癌中甲状腺过氧化物酶和钠碘同向转运体基因的低表达相关。
Endocr Relat Cancer. 2008 Jun;15(2):511-20. doi: 10.1677/ERC-07-0130.
10
Early clinical studies of novel therapies for thyroid cancers.甲状腺癌新疗法的早期临床研究。
Endocrinol Metab Clin North Am. 2008 Jun;37(2):511-24, xi. doi: 10.1016/j.ecl.2008.02.005.
Zotero 插件